Paper2858720
Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.
Littlewood JM and 3 others. Lancet, 1985. Cited by 196 papers, by iCite.
Cite this record
ConductScience Library. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Papers, record 2858720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2858720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colistin | Major topic |
| Cystic Fibrosis | Major topic |
| Pseudomonas Infections | Major topic |
| Adolescent | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Infant | |
| Male | |
| Respiratory Tract Infections |
Source PubMed
Cited by48
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 196 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39811797 | Cystic fibrosis and the clinical biofilm revolution A survey of the Danish CF Center's contribution. | Biofilm | 2025 | https://conductscience.org/library/papers/39811797 | PubMed |
| 37663252 | Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37663252 | PubMed |
| 37268599 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. | Cochrane Database Syst Rev | 2023 | https://conductscience.org/library/papers/37268599 | PubMed |
| 34072189 | Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives. | Microorganisms | 2021 | https://conductscience.org/library/papers/34072189 | PubMed |
| 33255354 | Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases. | J Clin Med | 2020 | https://conductscience.org/library/papers/33255354 | PubMed |
| 32696837 | Effectiveness of a multistep Pseudomonas aeruginosa eradication treatment protocol in children with cystic fibrosis in Brazil. | J Bras Pneumol | 2020 | https://conductscience.org/library/papers/32696837 | PubMed |
| 31480862 | Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis. | Chron Respir Dis | 2019 | https://conductscience.org/library/papers/31480862 | PubMed |
| 31423143 | Effect of Inhaled Colistin on the Treatment of Ventilator-Associated Pneumonia due to Multi-drug Resistant Acinetobacter. | Tanaffos | 2019 | https://conductscience.org/library/papers/31423143 | PubMed |
| 31013936 | Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31013936 | PubMed |
| 28440853 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. | Cochrane Database Syst Rev | 2017 | https://conductscience.org/library/papers/28440853 | PubMed |
| 27694971 | The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions. | Nat Commun | 2016 | https://conductscience.org/library/papers/27694971 | PubMed |
| 25278817 | Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. | Core Evid | 2014 | https://conductscience.org/library/papers/25278817 | PubMed |
| 24489509 | Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis. | ScientificWorldJournal | 2013 | https://conductscience.org/library/papers/24489509 | PubMed |
| 24068273 | Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. | J Bras Pneumol | 2013 | https://conductscience.org/library/papers/24068273 | PubMed |
| 23135343 | Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. | Thorax | 2013 | https://conductscience.org/library/papers/23135343 | PubMed |
| 22919584 | Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy? | Front Cell Infect Microbiol | 2011 | https://conductscience.org/library/papers/22919584 | PubMed |
| 22623044 | Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. | J Pharm Sci | 2012 | https://conductscience.org/library/papers/22623044 | PubMed |
| 21351813 | Aztreonam lysine for inhalation solution in cystic fibrosis: profile report. | Paediatr Drugs | 2011 | https://conductscience.org/library/papers/21351813 | PubMed |
| 20836577 | Aztreonam lysine for inhalation solution: in cystic fibrosis. | Drugs | 2010 | https://conductscience.org/library/papers/20836577 | PubMed |
| 20692633 | Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. | Paediatr Respir Rev | 2010 | https://conductscience.org/library/papers/20692633 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2858720
GET https://conductscience.org/api/papers/v1/2858720/cited_by?page=2